Compartilhar
Informação da revista
Vol. 94. Núm. 6.
Páginas 764-765 (1 novembro 2019)
Compartilhar
Compartilhar
Baixar PDF
Mais opções do artigo
Visitas
5747
Vol. 94. Núm. 6.
Páginas 764-765 (1 novembro 2019)
Case Letter
Open Access
Merkel cell carcinoma in an immunocompetent male statin user
Visitas
5747
Isaura Azevedo Fasciania,
Autor para correspondência
isafasciani@hotmail.com

Corresponding author.
, Luisa Groba Bandeiraa, Neusa Yuriko Sakai Valentea,b, Maria Fernanda Vieira Cunha Camargoa
a Department of Dermatology, Hospital do Servidor Público Estadual, Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, SP, Brazil
b Department of Dermatopathology, Hospital do Servidor Público Estadual, Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, SP, Brazil
Este item recebeu

Under a Creative Commons license
Informação do artigo
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Figuras (3)
Mostrar maisMostrar menos
Texto Completo
Dear Editor,

Merkel cell carcinoma (MCC) is a neuroendocrine primary cutaneous neoplasm with aggressive behavior. It presents high risk of local recurrence, as well as involvement of lymph nodes and distant metastases, which explains its high lethality, recommending its early recognition and treatment.

A 67-year-old male patient presented to the Dermatology Outpatient Clinic with a history of systemic arterial hypertension, type 2 diabetes mellitus, and dyslipidemia, using insulin, losartan, hydrochlorothiazide, atenolol, acetylsalicylic acid, rosuvastatin, and fibrate, six months after an asymptomatic, rapidly growing, erythematous-violaceous nodule (Fig. 1) measuring 3cm had appeared on his right leg, without palpable lymphadenomegalies. Incisional biopsy of the lesion (Figs. 2 and 3) revealed, in the histopathology, a dermal tumor with trabecular arrangement, composed of small blue cells with scarce cytoplasm and compact nuclei. Immunohistochemistry was positive for chromogranin and cytokeratin 20, signaling the diagnosis of MCC. In the outpatient return, we requested a computed tomography (CT) scan of the chest, abdomen, and pelvis, which did not show involvement of the internal organs or lymph node enlargement. In addition to the immunosuppression tests, the serologies were also all negative. The patient was then referred for oncological surgery, where sentinel lymph node screening was performed, which did not show any neoplastic involvement. Extensive excision, measuring 7.7cm×6.8cm×0.8cm, was performed and the histopathology demonstrated MCC with resection margins free of involvement.

Figure 1.

Fast-growing 3cm erythematous-violaceous nodule in right leg.

(0.07MB).
Figure 2.

Dermal tumor with trabecular arrangement, composed of small blue cells with scarce cytoplasm and compact nuclei (Hematoxylin & eosin, x20).

(0.09MB).
Figure 3.

Detail of the Merkel cells (Hematoxylin & eosin, x200).

(0.18MB).

MCC is a rare, aggressive, cutaneous neuroendocrine neoplasm that has shown a significant increase in incidence over recent years, presenting as erythematous-violaceous papule or nodule, usually painless and fast growing. It appears most often in sun-exposed areas, such as the head and neck, but also occurs in the extremities, trunk, and genitalia.1

MCC most often affects men, with a male-to-female ratio of 1.5 to 2:1; the elderly, with a mean age of 73 years in males and 76 years in females; and the immunocompromised, such as transplant recipients and HIV carriers, in the which it usually occurs ten years earlier than the average.2

In 2008, MCC was related to Polyomaviridae infection in 80% of cases, when it was identified in tumor cells’ DNA sequences of a new human polyomavirus, known as polyomavirus of Merkel cells. The frequency of this polyomavirus ranges from 9% in individuals aged 1–4 years to 80% in individuals over 50.3 More recently, an increase in MCC cases has been reported in younger subjects using statins.4

Statins have been widely used because of their effect on lowering blood cholesterol and for having a well-established role in preventing cardiovascular and cerebrovascular events. They also has an immunomodulatory effect on the negative regulation of MHCII expression. There is a shift from Th1 (T helper cells) to Th2, which leads to the increase of B cells, activating the excessive production of antibodies, besides exerting an inhibitory effect on natural killer cells (NKs), which are crucial for natural immunity against intracellular pathogens, thus compromising immune vigilance against viral infections and predisposing to tumor cell proliferation.5

Hence, it is possible to infer that statins predispose to Polyomaviridae infection and the consequent proliferation of MCC tumor cells, a phenomenon similar as that occurring with the immunocompromised.

Because of the rarity of the tumor, there is currently no standard consensus for treatment. One recommendation is broad surgical excision with free margins of 2cm and adjuvant or isolated radiotherapy.5

We report a case of MCC in an immunocompetent patient with a diagnosis below the average age of those diagnosed with MCC, with no history of other skin cancers, and a chronic statin user, thus strengthening the correlation between MCC and statin use.

Financial support

None declared.

Author's contributions

Isaura Azevedo Fasciani: Elaboration and writing of the manuscript.

Luisa Groba Bandeira: Obtaining, analyzing and interpreting the data; critical review of the manuscript.

Neusa Yuriko Sakai Valente: Approval of the final version of the manuscript; effective participation in research orientation; critical review of the literature; critical review of the manuscript.

Maria Fernanda Vieira Cunha Camargo: Conception and planning of the study; obtaining, analyzing and interpreting the data; critical review of the literature.

Conflicts of interest

None declared.

References
[1]
J. Albores-Saavedra, K. Batich, F. Chable-Montero, N. Sagy, A.M. Schwartz, D.E. Henson.
Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study.
J Cutan Pathol, 37 (2010), pp. 20-27
[2]
V. Dinh, L. Feun, G. Elgart, N. Savaraj.
Merkel cell carcinomas.
Hematol Oncol Clin North Am, 21 (2007), pp. 527-544
[3]
P. Czapiewski, W. Biernat.
Merkel cell carcinoma – recent advances in the biology, diagnostics and treatment.
Int J Biochem Cell Biol, 53 (2014), pp. 536-546
[4]
H. Sahi, V. Koljonen, T. Böhling, P.J. Neuvonen, H. Vainio, A. Lamminpää, et al.
Increased incidence of Merkel cell carcinoma among younger statin users.
Cancer Epidemiol, 36 (2012), pp. 421-424
[5]
L. Mascitelli, M.R. Goldstein.
Do the immunosuppressive effects of statins increase Merkel cell carcinoma risk?.
Int J Dermatol, 53 (2014), pp. e406-e409

How to cite this article: Fasciani IA, Bandeira LG, Valente NYS, Camargo MFVC. Merkel cell carcinoma in an immunocompetent male statin user. An Bras Dermatol. 2019;94:764–5.

Study conducted at the Hospital do Servidor Público Estadual, Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, SP, Brazil.

Copyright © 2019. Sociedade Brasileira de Dermatologia
Baixar PDF
Idiomas
Anais Brasileiros de Dermatologia (Portuguese)
Opções de artigo
Ferramentas
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.